Both are reasonable long-term options.
Durability of the early benefits of endovascular repair compared with open repair of abdominal aortic aneurysm (AAA) remains hard to pin down (JW Cardiol May 19 2010). Now, researchers from 42 Veterans Affairs medical centers present long-term follow-up data (up to 9 years; mean, 5.2) from the OVER trial involving 881 patients with AAA (mean age, 70) who were candidates for both endovascular and open repair and were randomly assigned to one or the other (JW Cardiol Dec 9 2009).
Functional Capacity in Heart Failure: Which Test, and for What Purpose?
As a prognostic tool, the 6-minute walk test was as good as cardiopulmonary exercise testing, but neither added much to clinical and demographic markers.
An Encouraging Trial of a Mesh-Covered Stent in Primary Percutaneous Coronary Intervention
Compared with other devices, a bare-metal stent with a mesh covering to trap potentially embolic material was associated with a higher rate of ST-segment resolution.
In three separate phase II trials, a proprotein convertase subtilisin/kexin type 9 protease inhibitor achieves significant reductions in LDL levels compared with placebo or ezetimibe.
Statin therapy, which reduces both low-density lipoprotein cholesterol (LDL-C) levels and cardiovascular risk, is unsuccessful in many patients because of poor response, intolerance, allergy, or a combination of the three. Nonstatin agents also lower LDL-C levels; to date, however, few data support their effectiveness at improving clinical outcomes. Attention is now focused on investigational, fully human, monoclonal antibodies directed against proprotein convertase subtilisin/kexin type 9 (PCSK9), which impairs the liver's ability to remove LDL-C from the blood. In three manufacturer-sponsored phase II studies of a subcutaneously administered PCSK9 inhibitor, AMG 145, investigators assessed the potential of this approach in different patient cohorts with or at risk for cardiovascular disease.
Heart Failure with Breast Cancer Chemotherapy: A Risk Worth Taking Seriously
Findings from a large database suggest that trastuzumab is associated with higher rates of HF or cardiomyopathy in clinical practice than it was in clinical trials.
Rate Control for Atrial Fibrillation: What Is the Best Drug to Use?
In a small, randomized crossover trial of four commonly prescribed beta- and calcium-channel blockers, diltiazem emerged the winner.
Incidence of Pulmonary and Venous Thromboembolism in Pregnancies After in vitro Fertilisation: Cross Sectional Study
Peter Henriksson, professor, Eli Westerlund, physician, PhD student, Hċkan Wallén, associate professor, Lena Brandt, biostatistician, Outi Hovatta, professor, Anders Ekbom, professor
Effect of Not Monitoring Residual Gastric Volume on Risk of Ventilator-Associated Pneumonia in Adults Receiving Mechanical Ventilation and Early Enteral Feeding
A Randomized Controlled Trial
Jean Reignier, MD, PhD; Emmanuelle Mercier, MD; Amelie Le Gouge, MSc; Thierry Boulain, MD; Arnaud Desachy, MD; Frederic Bellec, MD; Marc Clavel, MD; Jean-Pierre Frat, MD; Gaetan Plantefeve, MD; Jean-Pierre Quenot, MD; Jean-Baptiste Lascarrou, MD; for the Clinical Research in Intensive Care and Sepsis (CRICS) Group
Failure to Renew Prescriptions for Gastroprotective Agents to Patients on Continuous Non-Steroidal Anti-Inflammatory Drugs Increases Rate of Upper Gastrointestinal Injury
Le Ray I, Barkun AN, Vauzelle-Kervroëdan F, Bardou M
Dietary Sugars and Body Weight: Systematic Review and Meta-analyses of Randomised Controlled Trials and Cohort Studies
Lisa Te Morenga, research fellow, Simonette Mallard, research assistant, Jim Mann, professor